AKTX Akari Therapeutics Plc
Price Chart
Executive Summary
Akari Therapeutics entered into a securities purchase agreement to raise approximately $5.5 million in gross proceeds through a three-tranche private placement priced at $3.74 per ADS. The offering includes pre-funded warrants exercisable immediately and three series of warrants (Series H, I, J) with a $3.74 strike price and 5-year term, all subject to shareholder approval. The company also terminated its existing equity line with White Lion Capital, removing the overhang of that facility.
Key Financial Metrics
Actionable Insight
Expect immediate selling pressure given the highly dilutive structure relative to market cap. The three-tranche structure with escalating dilution at $3.74/share (near current price) suggests material share overhang. Monitor the annual meeting for shareholder vote on warrant shares; failure could trigger adverse terms. The lock-up on the White Lion facility is a positive but minor offset.
Key Facts
- Gross proceeds of ~$5.5 million from a three-tranche private placement priced at $3.74 per ADS
- Initial closing of $1,833,333 expected May 27, 2026, with second and third closings on June 15 and July 15
- Each tranche includes Series H, I, and J warrants exercisable at $3.74 for five years, in an amount equal to 100% of the ADSs purchased per tranche
- Company must seek shareholder approval at its 2026 annual meeting to issue the warrant shares
- The August 2025 purchase agreement with White Lion Capital remains in effect but is subject to a lock-up restricting further draws for 45 days
- Proceeds to be used for working capital purposes
- Market cap is approximately $6M, making this offering size very large relative to existing equity
- 80% of analysts rate the stock a Buy or Strong Buy, suggesting this dilutive financing may signal more acute capital needs than previously understood
Financial Impact
~$5.5M gross proceeds with severe dilution relative to a ~$6M market cap; potential for further dilution from warrant exercises
Risk Factors
- Massive dilution at $6M market cap — total potential shares including warrants could far exceed current float
- Shareholder approval may be difficult to obtain given the magnitude of dilution
- Downward price pressure as investors price in dilutive overhang
- Second and third closings are not guaranteed — if conditions fail, the company may still need additional capital
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025037 |
| Exhibit: ex4-1.htm | 0001493152-26-025037 |
| Exhibit: ex4-3.htm | 0001493152-26-025037 |
| Exhibit: ex4-4.htm | 0001493152-26-025037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
12d ago
|
Press Release
| $22.05 $14.99 | ▼ −32.04% | ▼ −31.99% | $15.44 (−29.95%) |
|
May 22, 2026
18d ago
|
8-K
| $17.81 $13.43 | ▲ +24.59% | ▲ +25.68% | $15.44 (+13.28%) |
|
May 21, 2026
19d ago
|
Press Release
| $5.14 $22.05 | ▼ −328.99% | ▼ −327.39% | $15.44 (−200.49%) |
|
May 12, 2026
28d ago
|
Press Release
| $3.06 $3.50 | ▲ +14.38% | ▲ +14.30% | $15.44 (+404.74%) |
|
Apr 16, 2026
7w ago
|
EFFECT
| $5.12 $6.00 | ▼ −17.19% | ▼ −16.20% | $15.44 (−201.66%) |
|
Apr 9, 2026
8w ago
|
Press Release
| $3.92 $5.12 | ▲ +30.61% | ▲ +27.43% | $15.44 (+294.01%) |
|
Apr 6, 2026
9w ago
|
Press Release
| $3.54 $4.25 | ▲ +20.00% | ▲ +15.87% | $15.44 (+336.30%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $6.52 $5.48 | ▼ −15.95% | ▼ −15.24% | $15.44 (+136.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access